Navigation Links
Experimental vaccine protects nonhuman primates when given after exposure to Marburg virus

Using multi-disciplinary analysis that included cognitive, neurophysiologic, virologic, and molecular techniques, the team found both a low-level viral infection in the brain and immune cells that had infiltrated the brain in order to protect against the virus.

"As in the rest of the body, in the brain immune cells achieve a level of control of the virus, but are unable to clear the infection," says Howard Fox, associate professor at Scripps Research and director of Scripps NeuroAIDS Preclinical Studies center, who led the study. "Over the long-term, this immune response may act as a double-edged sword, protecting against rampant viral replication in the brain but leading to brain dysfunction."

The paper was published in the April 26 issue of the Journal of Neuroscience, the official journal of the Society of Neuroscience.

The study addresses a significant health problem. About one quarter to one third of all AIDS patients suffer from some form of central nervous system disorder in the course of their infection, ranging from minor cognitive and motor disorders to severe dementia, collectively known as neuroAIDS. Even subtle neurocognitive disorders limit quality of life with symptoms such as fatigue, and are correlated with difficulties ranging from a higher rate of traffic tickets to increased mortality.

In recent years, access to potent antiretroviral drugs in the United States and other developed countries has significantly improved the health, survival, and functioning of HIV-infected individuals. But since people are living longer with the virus, the overall prevalence of neuroAIDS appears to be increasing.

"Now that we're better at treating the immune/viral aspect of HIV, in many ways [AIDS] has turned into a chronic disease," says Fox. "The fact that many of the antiretroviral drugs do not show good penetration of the blood-brain barrier further puts the brain at risk, since the brain is infected soon after HIV exposu re and infection."

While previous studies had linked end-stage dementia due to HIV to the presence of infected and activated immune cells, the nature of neurological changes in earlier stages of the disease, the so-called "chronic phase," were unknown-until now.

Using simian immunodeficiency virus-infected models in the chronic phase, the research team found both virus and infiltrating lymphocytes (CD8+ T cells) in the brain. Molecular analysis revealed that the expression of several immune response genes was increased, including CCL5, which has multiple effects on neurons as well as immune cells. CCL5 was significantly upregulated throughout the course of infection, and was present in the infiltrating lymphocytes.

In addition to Fox, authors of the April 26, 2006 Journal of Neuroscience (Volume 26, Number 17) paper, titled "Host Response and Dysfunction in the CNS During Chronic SIV Infection," are: Eleanor Roberts, Salvador Huitron-Resendiz, Michael Taffe, Cecilia Marcondes, Claudia Flynn, Caroline Lanigan, Jennifer Hammond, Steven Head, and Steven Henriksen.


'"/>

Source:Public Health Agency of Canada


Related biology news :

1. NIAID Initiates Trial of Experimental Avian Flu Vaccine
2. Experimental shingles vaccine proves effective in nationwide study
3. Experimental TB drug effective against resistant and latent mycobacterium tuberculosis
4. Experimental drug reverses key cognitive deficits, pathology in Alzheimers
5. Experimental RNA-based drug kills prostate cancer cells effectively and safely
6. Experimental vaccine protects lab animals against several strains of H5N1
7. Experimental vaccine protects mice against deadly 1918 flu virus
8. Experimental cancer drugs counter muscle deterioration seen in muscular dystrophy
9. Experimental vaccine given during pregnancy reduces stillbirths from common virus
10. Research advances quest for HIV-1 vaccine
11. A much-needed shot in the arm for HIV vaccine development
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:3/23/2017)... 23, 2017 Research and Markets has announced ... & Trends - Industry Forecast to 2025" report to their ... The ... CAGR of around 8.8% over the next decade to reach approximately ... the market estimates and forecasts for all the given segments on ...
(Date:3/22/2017)... 2017 Optimove , provider of ... such as 1-800-Flowers and AdoreMe, today announced two ... Replenishment. Using Optimove,s machine learning algorithms, these features ... replenishment recommendations to their customers based not just ... customer intent drawn from a complex web of ...
(Date:3/20/2017)... At this year,s CeBIT Chancellor Dr. Angela Merkel ... came to the DERMALOG stand together with the Japanese Prime Minster Shinzo ... At the largest German biometrics company the two government leaders could see ... as well as DERMALOG´s multi-biometrics system.   Continue ... ...
Breaking Biology News(10 mins):
(Date:3/27/2017)... Md. , March 27, 2017  The ... billion for 2016, according to a new report ... medical lab testing is performed to evaluate disease ... individual therapy, among other reasons.  The healthcare market ... Market , provides an overview of the ...
(Date:3/27/2017)... (PRWEB) , ... March 27, 2017 , ... ... method to engineer scalable and customizable vascular grafts in JoVE’s Video Journal, the ... lead to new and improved ways of treating coronary artery disease (CAD). Lam ...
(Date:3/24/2017)... March 24, 2017 MiMedx Group, Inc. (NASDAQ: ... human placental tissue allografts and patent-protected processes to develop ... of healthcare, announced today  that it will present at ... , NY.  Parker H. "Pete" Petit, Chairman and ... Christopher M. Cashman , EVP and Chief Commercialization ...
(Date:3/24/2017)... 2017 On Thursday, March 23, ... 5,817.69, down 0.07%; the Dow Jones Industrial Average edged ... 500 closed at 2,345.96, marginally dropping 0.11%. US markets ... green, 4 sectors finished in red, and 1 sector ... initiated reports coverage on the following Biotechnology equities: BioDelivery ...
Breaking Biology Technology: